CAR Cell Therapy
CAR T cell therapy produces targeted and sustained lymphodepletion through serial antigen-dependent killing. Autologous ex vivo manufacturing has been the main delivery model for autoimmune CAR cell therapy. In vivo CAR T generation avoids…
1 sources - 5 claims
CAR T cell therapy produces targeted and sustained lymphodepletion through serial antigen-dependent killing. Autologous ex vivo manufacturing has been the main delivery model for autoimmune CAR cell therapy. In vivo CAR T generation avoids ex vivo manufacturing by delivering CAR-encoding constructs directly into patients. Allogeneic CAR cell products are intended to support off-the-shelf treatment models. CAR T cell therapy is being applied to autoimmune diseases to achieve a durable immune reset with a single infusion.